Open access

Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
Wenwen Zhang, Shuang Tong, Bingyang Hu, Tao Wan, Haowen Tang, Feilong Zhao, Tianyu Jiao, Junfeng Li, Ze Zhang, Jinping Cai, Huiyi Ye, Zhanbo Wang, Shiqing Chen, Yafei Wang, Xuerui Li, Fangzhou Wang, Junning Cao, Lantian Tian, Xiaochen Zhao, Mingyi Chen, Hongguang Wang, Shouwang Cai, Minggen Hu, Yuezong Bai, Shichun Lu

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007366; DOI: 10.1136/jitc-2023-007366
Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach
Jie Zhao, Yayi He, Xue Yang, Panwen Tian, Liang Zeng, Kun Huang, Jing Zhao, Jiaqi Zhou, Yin Zhu, Qiyuan Wang, Mailin Chen, Wen Li, Yi Gao, Yongchang Zhang, Yang Xia

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007492; DOI: 10.1136/jitc-2023-007492
Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events
Karolina Gente, Leonore Diekmann, Lea Daniello, Julia Will, Manuel Feisst, Victor Olsavszky, Janine Günther, Hanns-Martin Lorenz, M Margarida Souto-Carneiro, Jessica C Hassel, Petros Christopoulos, Jan Leipe

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007557; DOI: 10.1136/jitc-2023-007557
ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models
Won Jong Jin, Luke M Zangl, Meredith Hyun, Elian Massoud, Kaleb Schroeder, Roxana A Alexandridis, Zachary S Morris

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007474; DOI: 10.1136/jitc-2023-007474
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
Ramin Salehi-Rad, Raymond J Lim, Yushen Du, Linh M Tran, Rui Li, Stephanie L Ong, Zi Ling Huang, Camelia Dumitras, Tianhao Zhang, Stacy J Park, William Crosson, Bitta Kahangi, Jensen Abascal, Christopher Seet, Michael Oh, Maryam Shabihkhani, Manash Paul, Kostyantyn Krysan, Aaron E Lisberg, Edward B Garon, Bin Liu, Steven M Dubinett

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e006896; DOI: 10.1136/jitc-2023-006896
Responses of patients with cancer to mRNA vaccines depend on the time interval between vaccination and last treatment
Lara Victoria Donhauser, Julia Veloso de Oliveira, Cordula Schick, Wenzel Manlik, Sabrina Styblova, Sarah Lutzenberger, Michael Aigner, Patrick Philipp, Sebastian Robert, Beate Gandorfer, Dirk Hempel, Louisa Hempel, Dietmar Zehn

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007387; DOI: 10.1136/jitc-2023-007387
Correction: Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e006802corr1; DOI: 10.1136/jitc-2023-006802corr1
Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Friedegund Meier, Peter Mohr, Katharina C Kähler, Michael Weichenthal, Axel Hauschild, Dirk Schadendorf, Selma Ugurel, Georg Lodde, Lisa Zimmer, Ralf Gutzmer, Dirk Debus, Bastian Schilling, Alexander Kreuter, Jens Ulrich, Frank Meiss, Rudolf Herbst, Andrea Forschner, Ulrike Leiter, Claudia Pfoehler, Martin Kaatz, Fabian Ziller, Jessica C Hassel, Michael Tronnier, Michael Sachse, Edgar Dippel, Patrick Terheyden, Carola Berking, Markus V Heppt, Felix Kiecker, Sebastian Haferkamp, Christoffer Gebhardt, Jan Christoph Simon, Stephan Grabbe, Carmen Loquai

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007630; DOI: 10.1136/jitc-2023-007630
Complete response to immunotherapy in a patient with high-risk stage III colorectal cancer after ctDNA-guided detection of early adjuvant treatment failure
Nicholas Lucchesi, Jenna M Ally, Matthew J Reilley

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007434; DOI: 10.1136/jitc-2023-007434
Siglec-9⁺ tumor-associated macrophages delineate an immunosuppressive subset with therapeutic vulnerability in patients with high-grade serous ovarian cancer
Yiying Wang, Mengdi He, Chen Zhang, Kankan Cao, Guodong Zhang, Moran Yang, Yan Huang, Wei Jiang, Haiou Liu

Journal for ImmunoTherapy of Cancer Sep 2023, 11 (9) e007099; DOI: 10.1136/jitc-2023-007099

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages